On August 30th, TUL held a mid-term performance conference for 2023 in Hong Kong. At the meeting, it was announced that the operating revenue of TUL in the first half of 2023 was RMB 6.906 billion, a year-on-year increase of 33.3%. Among them, the revenue from intermediates is 1.047 billion yuan, the revenue from the API is 3.423 billion yuan, and the revenue from pharmaceutical products is 2.436 billion yuan.